Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $25.00 target price on the stock.

A number of other analysts also recently issued reports on HUMA. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Humacyte in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Benchmark cut their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st. UBS Group reissued a “buy” rating on shares of Humacyte in a report on Monday, December 1st. Finally, Wall Street Zen downgraded Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.14.

Humacyte Stock Down 13.9%

Shares of NASDAQ HUMA opened at $1.05 on Monday. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The business has a 50-day moving average of $1.10 and a 200-day moving average of $1.46. The firm has a market capitalization of $196.63 million, a price-to-earnings ratio of -4.57 and a beta of 1.93. Humacyte has a 12 month low of $0.88 and a 12 month high of $4.14.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. The company had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.92 million. Sell-side analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humacyte

A number of large investors have recently bought and sold shares of the stock. CenterBook Partners LP boosted its stake in shares of Humacyte by 141.1% during the second quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after purchasing an additional 2,007,743 shares during the period. CWM LLC raised its holdings in Humacyte by 29,921.4% during the 2nd quarter. CWM LLC now owns 43,531 shares of the company’s stock valued at $91,000 after buying an additional 43,386 shares during the last quarter. Concurrent Investment Advisors LLC boosted its position in Humacyte by 17.5% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 51,115 shares of the company’s stock valued at $107,000 after buying an additional 7,615 shares during the period. LJI Wealth Management LLC grew its holdings in Humacyte by 27.4% in the 2nd quarter. LJI Wealth Management LLC now owns 288,000 shares of the company’s stock worth $602,000 after acquiring an additional 62,000 shares during the last quarter. Finally, Savant Capital LLC bought a new stake in Humacyte in the 2nd quarter worth $122,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte News Roundup

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: U.S. Department of Defense appropriations language in the FY2026 bill includes dedicated funding to evaluate and potentially procure Humacyte’s bioengineered blood vessels for traumatic vascular injuries — a credibility and market-access milestone that supporters view as a major long-term commercial catalyst. Humacyte Announces New U.S. Department of Defense Funding
• Positive Sentiment: Coverage from major outlets highlights the DoD funding and drove earlier buying interest, raising Humacyte’s profile for investors focused on defense procurement and trauma-care markets. Humacyte Shares Climb After Pentagon Issues Funding for Vascular Repair Tech
• Positive Sentiment: Analysts have responded: an independent firm reaffirmed a “buy” and published a very high $25 price target, which, while aggressive, may support bullish sentiment from momentum traders and long-term speculators. Benzinga
• Neutral Sentiment: Short-interest data posted for February appears unreliable/zero and offers no clear signal about bearish positioning; treat that report with caution. (No external link provided)
• Negative Sentiment: Despite the positive headlines, the stock is trading down today amid heavy volume — likely reflecting profit-taking after the run-up, the funding’s policy/appropriations nature (not an immediate purchase order), and broader fundamentals: Humacyte remains unprofitable with high leverage and a history of volatile swings. Coverage noted the sharper-than-market decline today. Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.